Login to Your Account

Genzyme, Osiris Ink $1.38B Stem Cell Products Deal

By Catherine Hollingsworth

Wednesday, November 5, 2008
Genzyme Corp. and Osiris Therapeutics Inc. have agreed to develop and commercialize two stem cell products, in a deal that would provide Osiris with up to $1.25 billion in potential milestone payments and $130 million up front. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription